Technical Analysis for CTSO - Cytosorbents Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.82 | 1.24% | 0.01 |
Earnings due: Apr 30
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Inside Day | Range Contraction | 1.24% | |
Wide Bands | Range Expansion | 1.24% | |
Wide Bands | Range Expansion | -0.33% | |
Oversold Stochastic | Weakness | -0.33% | |
20 DMA Resistance | Bearish | -6.83% |
Alert | Time |
---|---|
Possible NR7 | about 16 hours ago |
10 DMA Resistance | about 20 hours ago |
Rose Above 10 DMA | about 21 hours ago |
Fell Below Previous Day's Low | about 21 hours ago |
Down 1% | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 04/30/2024
Cytosorbents Corporation Description
CytoSorbents Corporation, a development stage company, is engaged in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Disease Imaging Medical Equipment Kidney Disease Dysfunction Interventional Radiology Membrane Technology Radiology Cytokine Toxins Blood Plasma Bypass Organs Perfusion Renal Dialysis Transfusion Medicine Acute Respiratory Distress Syndrome Sepsis Blood Products Bypass Surgery Cardiopulmonary Bypass Pancreatitis Adjunctive Therapy Cardiopulmonary Bypass Surgery Respiratory Distress Respiratory Distress Syndrome Toxic Chemicals
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.29 |
52 Week Low | 0.782 |
Average Volume | 102,249 |
200-Day Moving Average | 1.63 |
50-Day Moving Average | 0.93 |
20-Day Moving Average | 0.88 |
10-Day Moving Average | 0.82 |
Average True Range | 0.07 |
RSI (14) | 42.20 |
ADX | 16.36 |
+DI | 12.97 |
-DI | 13.53 |
Chandelier Exit (Long, 3 ATRs) | 0.82 |
Chandelier Exit (Short, 3 ATRs) | 0.99 |
Upper Bollinger Bands | 1.02 |
Lower Bollinger Band | 0.74 |
Percent B (%b) | 0.28 |
BandWidth | 31.97 |
MACD Line | -0.04 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0032 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.85 | ||||
Resistance 3 (R3) | 0.85 | 0.83 | 0.84 | ||
Resistance 2 (R2) | 0.83 | 0.83 | 0.83 | 0.84 | |
Resistance 1 (R1) | 0.83 | 0.82 | 0.83 | 0.83 | 0.84 |
Pivot Point | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 |
Support 1 (S1) | 0.81 | 0.81 | 0.81 | 0.81 | 0.80 |
Support 2 (S2) | 0.79 | 0.80 | 0.79 | 0.80 | |
Support 3 (S3) | 0.79 | 0.79 | 0.79 | ||
Support 4 (S4) | 0.79 |